Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, May 23, 2018
Eisai and Purdue Pharma to Present Latest Phase I Clinical Data on Lemborexant at 32nd Annual Sleep Meeting
Thursday, May 17, 2018
Eisai to Present Data on Oncology Pipeline and Products at 54th ASCO Annual Meeting
Monday, April 23, 2018
Eisai: Rights to Non-Opiod Severe Chronic Pain Treatment Prialt Transferred to Riemser
Friday, April 20, 2018
Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting
Thursday, April 19, 2018
Eisai: World's First Bile Acid Transporter Inhibitor "GOOFICE 5mg Tablet" Launched in Japan
Friday, April 13, 2018
Eisai Enters Into Joint Research Agreement With the Broad Institute, Colorado State University, and University of Chicago
Monday, April 2, 2018
Eisai Submits Supplemental New Drug Application to U.S. FDA
Wednesday, March 28, 2018
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement
Friday, March 23, 2018
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal
Eisai: Anticancer Agent LENVIMA Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: